Pfizer Inc

$ 38.74 -1.14 (-2.86%)
Volume: 47,919,166 Avg Vol (1m): 22,675,550
Market Cap $: 215.08 Bil Enterprise Value $: 238.35 Bil
P/E (TTM): 20.82 P/B: 3.54
Earnings Power Value 37.03
Net Current Asset Value -7.98
Tangible Book -4.37
Projected FCF 31.76
Median P/S Value 33.58
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 0.45
Equity-to-Asset 0.40
Debt-to-Equity 0.66
Debt-to-EBITDA 2.13
Interest Coverage 11.43
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.92
DISTRESS
GREY
SAFE
Beneish M-Score -2.65
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 14.69%
WACC 5.77%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 28.05
Net Margin % 20.79
ROE % 16.12
ROA % 6.73
ROC (Joel Greenblatt) % 80.77
3-Year Total Revenue Growth Rate 3.20
3-Year Total EBITDA Growth Rate 8.50
3-Year EPS w/o NRI Growth Rate 18.80

» PFE's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:PFE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare XSWX:ROG XSWX:NOVN NYSE:MRK NYSE:ABBV XTER:BAYN LSE:GSK XPAR:SAN NYSE:JNJ NYSE:LLY LSE:AZN NYSE:BMY TSE:4503 TSE:4519 TSE:4578 TSE:4568 HKSE:01093 TSE:4151 TSE:4528 SHSE:600436 SHSE:600867
Traded in other countries PFEBC.Belgium PFIZ34.Brazil 0Q1N.UK
Address 235 East 42nd Street, New York, NY, USA, 10017
Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing close to 50% of its total sales.

Ratios

Current vs industry vs history
PE Ratio (TTM) 20.82
Forward PE Ratio 13.81
N/A
PE Ratio without NRI 20.82
Price-to-Owner-Earnings 17.82
PB Ratio 3.54
PS Ratio 4.31
Price-to-Free-Cash-Flow 16.95
Price-to-Operating-Cash-Flow 14.6
EV-to-EBIT 18.07
EV-to-EBITDA 12.17
EV-to-Revenue 4.44
PEG Ratio 71.33
Shiller PE Ratio 20.49
Current Ratio 1.57
Quick Ratio 1.33
Days Inventory 256.30
Days Sales Outstanding 54.60
Days Payable 151.67

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.56
Dividend Payout Ratio 0.73
3-Year Dividend Growth Rate (Per Share) 6.70
Forward Dividend Yield % 3.61
N/A
Yield-on-Cost (5-Year) % 4.95
3-Year Share Buyback Rate 2.20

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.24
Price-to-Median-PS-Value 1.17
Earnings Yield (Joel Greenblatt) % 5.54
Forward Rate of Return (Yacktman) % 6.65

More Statistics

Revenue (TTM) (Mil) $ 53,647
EPS (TTM) $ 1.86
Beta 0.59
Volatility % 16.39
52-Week Range $ 34.37 - 46.47
Shares Outstanding (Mil) 5,551.8

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y